Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Antoinette Moran, MD
University of Minnesota
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Stanford University
Palo Alto, California, United States
- Barbara Davis Center
Aurora, Colorado, United States
- Yale University
New Haven, Connecticut, United States
- Indiana University
Indianapolis, Indiana, United States
- University of Minnesota
Minneapolis, Minnesota, United States
- Children'S Mercy Hospital
Kansas City, Missouri, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 May 2021
- Primary completion
- 18 Dec 2025
- Completion
- 18 Dec 2025
- Last update posted
- 20 Dec 2023
- Registered enrollment
- 77
- Registry id
- NCT06177691
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.